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Abstract
Despite a high current standard of care in antiretroviral therapy for HIV, multidrug-resistant strains continue to emerge,
underscoring the need for additional novel mechanism inhibitors that will offer expanded therapeutic options in the clinic.
We report a new class of small molecule antiretroviral compounds that directly target HIV-1 capsid (CA) via a novel
mechanism of action. The compounds exhibit potent antiviral activity against HIV-1 laboratory strains, clinical isolates, and
HIV-2, and inhibit both early and late events in the viral replication cycle. We present mechanistic studies indicating that
these early and late activities result from the compound affecting viral uncoating and assembly, respectively. We show that
amino acid substitutions in the N-terminal domain of HIV-1 CA are sufficient to confer resistance to this class of compounds,
identifying CA as the target in infected cells. A high-resolution co-crystal structure of the compound bound to HIV-1 CA
reveals a novel binding pocket in the N-terminal domain of the protein. Our data demonstrate that broad-spectrum antiviral
activity can be achieved by targeting this new binding site and reveal HIV CA as a tractable drug target for HIV therapy.
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Introduction
Highly active antiretroviral therapies (HAART) against human
immunodeficiency virus type 1 (HIV-1) have proven in recent years
to be extremely effective at reducing viral load and significantly
delaying disease progression [1]. However, there remains a pressing
need to discover and develop new classes of HIV inhibitors. The
virus continues to acquire resistance to currently administered
antiretroviral drugs and the rate of transmitted resistance is
increasing [2,3]. The discovery of compounds that inhibit the
replication of HIV-1 via new mechanisms offers the best hope of
generating drugs that are active against all HIV-1 variants in the
clinic. The potency of these compounds would not be affected by
mutations that confer resistance to existing therapies [4].
The capsid protein (CA) of HIV-1 plays critical roles in both late
and early stages of the viral replication cycle and is widely viewed as
an important unexploited therapeutic target [4,5,6]. At the earliest
stages of particle assembly, the interactions between CA domains of
the Gag polyprotein help drive the formation of immature particles at
the membrane of host cells [7]. After the releaseof immature particles
from infected cells, proteolytic processing of the Gag polyprotein is
completed, leading to capsid assembly and formation of the mature
virus. During assembly, the viral RNA genome is packaged into a
capsid particle composed of a lattice of CA protein hexamers that
form a distinct fullerene cone shaped particle [8]. After virus fusion
with a target cell, the core is released into the cytoplasm and CA is
thought to undergo a controlled disassembly reaction in order for
reverse transcription of the viral genome to occur properly [9].
The HIV-1 CA protein has attracted increased interest as a drug
discovery target in recent years. A small molecule, CAP-1, and two
versions of a peptide inhibitor, CAI and NYAD-1, have been
describedthat targetHIV-1CAinvitroandappearto interferewith
CA function in infected cells [10,11,12]. In addition, high resolution
structural data on the hexameric lattice that forms the full core
structure has been reported [13,14]. These structures illustrate the
distinct roles and importance of inter-subunit interfaces in the CA
complex and have shed some light on the potential mechanisms of
previously reported CA assembly inhibitors.
PLoS Pathogens | www.plospathogens.org 1 December 2010 | Volume 6 | Issue 12 | e1001220Here we describe a novel series of antiviral compounds that
target HIV-1 CA in infected cells and appear to interfere with
both the viral uncoating process and the formation of infectious
particles. Mechanism-of-action and in vitro resistance studies of this
series are described. A high resolution co-crystal structure has been
determined and illustrates a novel binding pocket in the N-
terminal domain (NTD) of HIV-1 CA that is distinct from any
previously described. We demonstrate that targeting this new
binding pocket with small molecules results in broad-spectrum
antiviral activity. This study provides the starting point, where
structure-based drug design is a viable option, for the development
of a new class of HIV therapeutics.
Results
In vitro Antiviral Activity
PF-1385801 was identified as a hit in a high throughput screen
for inhibitors of HIV replication [15]. Several analogs of this
compound demonstrated activity in antiviral assays using the MT-
2 T-cell line and HIV-1 NL4-3. PF-1385801 inhibited HIV-1
replication with a 50% effective concentration (EC50) of 4.5 mM
and exhibited a 50% cytotoxic concentration (CC50)o f6 1mM,
resulting in a therapeutic index (TI, CC50/EC50) of 14 (Fig. 1).
More potent analogs were subsequently designed and synthesized,
as detailed in Fig. 1.
A key issue in the development of novel HIV drugs is the
potential therapeutic spectrum (consistency of activity across
multiple strains of HIV). To address this, two of the compounds
were evaluated in antiviral assays using peripheral blood
mononuclear cells (PBMCs) infected with a diverse set of HIV-1
lab strains and clinical isolates covering 6 clades and both X4 and
R5 tropic viruses (Fig. 2). PF-3450074 and PF-3759857 were
active against all strains of HIV-1 tested with median EC50 values
of 0.207 (range 0.113 to 0.362 mM) and 1.17 (range 0.51 to 3.17)
mM, respectively (Fig. 2 and Tables S1 and S2). In addition, PF-
3759857 was active against HIV-2 with an EC50 of 4.7 mM. This
tight spectrum of activities against HIV-1 compared well with the
marketed drugs, AZT, a nucleoside analog, and efavirenz (EFV), a
non-nucleoside reverse transcriptase inhibitor (NNRTI) (Fig. 2 and
Tables S3 and S4).
In vitro Resistance Studies to Identify the Antiviral Target
To positively identify the antiviral target of this class of
inhibitors, PF-1385801 resistant viral variants were selected in in
vitro serial passage experiments. Sequence analysis of cDNAs
derived from resistant viral variants selected in the presence of PF-
1385801 revealed a single mutation, T107N, located in the NTD
of the CA protein. No mutations associated with resistance
selection were identified in the integrase or reverse transcriptase
Author Summary
Although the current standard of care for Human
Immunodeficiency Virus (HIV) is high, viral resistance has
emerged to every drug currently in the clinic, in some
cases rendering the entire class ineffective for patients. A
new class of antiretroviral drugs would be effective against
strains of HIV-1 that are resistant to any existing drug and
would expand the therapeutic options available to
patients. Capsid is the primary structural protein of HIV
and a critical part of the viral replication cycle, both in the
assembly of viral particles and in the infection of host cells.
We report a new class of antiretrovirals that targets HIV-1
capsid and demonstrate that it is active at two critical
stages in the viral replication cycle. These compounds
were consistently effective against a range of clinical
strains of HIV-1, from various sub-types, as well as HIV-2.
Finally, the compounds bind in a unique pocket on capsid
that has not previously been highlighted as a drug binding
site. We believe this new class of antiretrovirals can serve
as a starting point for the development of a new gene-
ration of HIV-1 therapeutics and, more generally, under-
scores the potential of capsid as a therapeutic target.
Figure 1. Structures and antiviral activities of inhibitors that target HIV-1 capsid. Antiviral activity was determined in CPE assays after
infection of MT-2 cells with HIV-1 NL4-3. Results represent the mean 6 standard deviations from 4–6 experiments, or the mean with individual values
from 2 experiments. TI, therapeutic index is the ratio of mean CC50: mean EC50.
doi:10.1371/journal.ppat.1001220.g001
Novel Mechanism and Binding Site for HIV Capsid
PLoS Pathogens | www.plospathogens.org 2 December 2010 | Volume 6 | Issue 12 | e1001220coding sequences. Recombinant HIV-1 NL4-3 virus encoding the
T107N substitution in HIV-1 CA exhibited an 11-fold reduction
in susceptibility to PF-1385801 when compared to wild-type NL4-
3 (Table 1). Similar reductions in susceptibility were observed for
PF-3450071 (6-fold) and PF-3759857 (10-fold), while no shift was
observed for EFV (NNRTI) or the integrase inhibitor AG-110079.
In subsequent in vitro resistant virus selection experiments using a
compound with a larger TI, PF-3759857, additional substitutions
were identified in CA (T107N, H87P, Q67H, K70R and L111I),
after 53 days in culture. Virus isolated from the final passage of
this experiment showed a .60-fold reduction in susceptibility
to PF-3759857 and recombinant NL4-3 virus encoding the five
substitutions (5M) exhibited a .40-fold reduction in susceptibility
to PF-3450074 (up to the cytotoxicity limit of the compound).
Wild-type NL4-3, the T107N mutant, and the 5M mutant virus all
exhibited similar levels of infectious virus production from
transfected cells and comparable levels of viral replication in
reporter gene-based infection assays (in the absence of compound),
suggesting that the substitutions do not significantly impair
replication capacity. However, more detailed studies, such as
direct competition assays are required to accurately determine if
the substitutions affect replication fitness.
These results demonstrate that mutation(s) in HIV-1 CA (e.g.
T107N) are sufficient to confer resistance to this new class of
inhibitors and demonstrate that HIV-1 CA is the target in infected
cells. Although additional work is needed to determine the
individual contributions of the mutations identified in addition
to T107N, it appears that more than one mutation is required to
generate high levels of resistance to this inhibitor class. While it is a
definitive tool for target identification, it should be noted that in
vitro selection can be used to generate resistant mutants to any
known antiviral and does not accurately predict the clinical barrier
to resistance, which is a function of several in vivo parameters,
including the pharmacokinetics of the compound.
Inhibition of Early Events in the HIV-1 Replication Cycle
To determine the stage of the replication cycle targeted by this
new class of compounds, PF-3450071 and PF-3450074 were
evaluated in single cycle infection assays. Such assays monitor the
early steps of infection up to the integration of the viral cDNA into
the host cell chromosome and expression of that sequence. PF-
3450071 and PF-3450074 were tested in parallel infections with
single-cycle HIV-1 virus packaged with either wild type HIV-1
envelope (NL4-3 pseudovirus) or vesicular stomatitis virus gly-
coprotein (VSVG), an envelope that allows viral entry by an
alternative mechanism (VSV pseudovirus). In addition, three
compounds with known mechanisms, AMD3100 (HIV CXCR4/
entry inhibitor), EFV (NNRTI/early mechanism) and NFV
(protease inhibitor (PI)/late mechanism) were evaluated in the
assays. PF-3450071 and PF-3450074 were active against both the
NL4-3 and VSV pseudoviruses (Table 2). This inhibition profile
was similar to EFV. The profile was distinct from that of
AMD3100, which inhibited the HIV-1 envelope NL4-3 pseudo-
virus, but not the VSVG pseudovirus, and NFV which was not
active in the assay (Table 2). These data indicate that PF-3450071
and PF-3450074 act early in the HIV-1 replication cycle at a step
following HIV-1 envelope-mediated entry.
Elucidating the Early Stage Mechanism
To begin dissecting the early events of infection, DNA was
isolated from single cycle infections of MT-2 cells in the presence
or absence of inhibitors and analyzed by quantitative PCR. Primer
sets were used that detect total viral cDNA produced, 2-LTR
circles (a nuclear episomal form of the viral cDNA), or provirus
(the viral genome integrated into host cell chromosomes) as
described previously [16]. PF-3450074 inhibited the accumulation
of total viral cDNAs (9% of control) and as result inhibited
the levels of integrated provirus DNA measured (2% of control)
Figure 2. Activity of inhibitors against diverse strains of HIV-1. The spectrum of antiviral potencies was determined for two capsid inhibitors,
efavirenz, and zidovudine against a panel of HIV isolates including clinical isolates and laboratory adapted strains. Each dot in the figure represents
the geometric mean EC50 value for a single HIV isolate. The variability of the antiviral spectrum is further illustrated for each compound with a
superimposed ‘‘box whisker’’ plot. The box represents the inter-quartile range and the whiskers highlight the 95% confidence interval. The vertical
line in the box represents the geometric mean of the EC50 values.
doi:10.1371/journal.ppat.1001220.g002
Table 1. In vitro anti-viral activity against HIV-1 capsid wt and
T107N mutant.
EC50 (mM) against HIV NL4-3
a
Compound Wild type T107N FC
b P
c
PF-1385801 2.761.4 2867.1 11 0.015
PF-3450071 0.7260.23 4.561.1 6 0.014
PF-3759857 2.561.1 2469.5 10 0.014
EFV 0.001260.00013 0.0006460.00002 1 nd
AG-110079 0.003760.0016 0.003860.0031 1 nd
aEC50 values were determined in full replication assays (not CPE).
bFC=Fold-change calculated by dividing the mutant (T107N) EC50 by the WT
EC50.
cP=P-value, determined using the student’s T-test.
doi:10.1371/journal.ppat.1001220.t001
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inhibitor EFV, indicating that PF-3450074 either inhibits reverse
transcription or a step prior to it. In contrast, the integrase
inhibitor, AG-110079, resulted in a 4-fold increase in 2-LTR circle
accumulation and minimal reduction in total viral cDNA (78% of
control) (Fig. 3a). As the profile for PF-3450074 did not match that
of the integrase inhibitor control, integrase inhibition can be ruled
out as a possible mechanism.
To further analyze the mechanism of action, the inhibition
profile of PF-3450071 was compared to that of AMD3100 and
EFV in synchronized time-of-addition experiments, where inhib-
itors are added a various time points following infection to monitor
Table 2. Activity of antiviral compounds in selected assays.
Compound (Target) Activity in specified assay (EC50 mM)
a Stage of action
NL43 Pseudovirus VSV-G Pseudovirus Production/Infection
PF-3450071 (capsid) 0.51 0.39 0.78 Early/Late
PF-3450074 (capsid) 0.55 0.32 0.33 Early/Late
AMD3100 (viral entry) 0.002 .100 n.d. Entry
Efavirenz (RT) 0.001 0.001 .1 Early
NFV (Protease) .10 n.d. 0.077 Late
aAntiviral activity was determined after infection of HeLa CD4 LTR/beta-Gal cells with HIV single-cycle infectious viruses packaged with either the NL4-3 or VSV-G
envelope proteins.
doi:10.1371/journal.ppat.1001220.t002
Figure 3. Identification of mechanism of action. a) HIV DNA quantification. A Taqman quantitative PCR assay was performed to determine the
effect of test compounds on the levels of total HIV DNA, 2-LTR circles and integrated provirus generated during infection. The data is presented as a
percentage of amounts observed in an untreated control tested in parallel. b) Time-of-addition experiment. HeLa CD4 LTR/beta-Gal reporter cells
were infected with HIV-1 (NL43) and test compounds (at 26EC 90) were added at different times after infection. Reporter signal was monitored at
72 h post-infection as a measure of replication. c) Effect of PF-3450074 in a virus production assay. 293T cells transfected with pNL43 were incubated
in varying concentrations of PF-3450074. After 48 hours supernatants were transferred to HeLa CD4 LTR/beta-Gal reporter cells. The line graph shows
the percentage of b galactosidase production compared with a mock treated control. Solid bars indicate the concentration of HIV capsid protein
(p24) secreted by the 293T cells at each concentration tested. d) Kinetics of CA multimerization. HIV CA spontaneously multimerizes in the presence
of high salt, causing a change in optical density. Test compounds were incubated with CA protein and multimerization was initiated with the addition
of concentrated salt solution.
doi:10.1371/journal.ppat.1001220.g003
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AMD3100, showed a dramatic early loss in activity, even within
the first two hours of infection. The NNRTI, EFV, retained the
majority of inhibitory activity (.78%) when added up to 4 hours
after infection and lost activity thereafter, with a mid-point around
6 hours after infection. PF-3450071 displayed a profile that was
distinct from both comparators. The compound maintained the
majority of its inhibitory activity (.84%) when added up to
2 hours after infection, and lost significant levels of activity when
added 3 or more hours after infection (Fig. 3b). These results
suggest that this new class of HIV-1 inhibitor targets an early step
in the virus replication cycle, after viral entry but before reverse
transcription, possibly viral uncoating. Consistent with these data,
PF-3450074 did not inhibit recombinant HIV-1 RT in standard
biochemical assays (IC50.100 mM).
Inhibition of Late Events in the HIV-1 Replication Cycle
Virus production-infectivity assays were conducted to determine
if compounds affect the late stages of viral replication. Infectious
virus was expressed from transfected producer cells in the presence
or absence of compound and the infectivity of the resulting virus
was tested by diluting the supernatant on to an indicator cell line.
As infectious virus is produced from a transfected DNA, bypassing
the early stages of the replication cycle, only inhibitors targeting
the later stages of viral replication (i.e. post-integration) should
show activity in the assay. We tested two compounds (PF-3450071
and PF-3450074) in the viral production-infectivity assay using
NFV (PI) and EFV (NNRTI) as late stage and early stage inhibitor
controls. Both PF-3450071 and PF-3450074 inhibited the pro-
duction of infectious virus with EC50 values of 0.78 and 0.33 mM,
respectively (Table 2). As expected the HIV-1 PI, NFV, inhibited
infectious virus production while the RT inhibitor, EFV was not
active in the assay (Table 2). Notably, the overall levels of Gag
proteins released into the supernatant of transfected cells were not
affected by PF-3450074, as measured by p24 ELISA (Fig. 3c).
Thus, this series does not inhibit HIV-1 particle production but
renders the nascent particles noninfectious.
Western blot analysis of viral supernatants with antibodies
directed against the HIV-1 CA protein (p24) showed that PF-
3450071 did not affect HIV-1 Gag proteolytic processing (Fig. S1),
which demonstrates that the compounds do not inhibit HIV-1
protease or virion maturation in the manner described for
inhibitors such as Bevirimat (PA-457) [17] and PF-46396 [18].
Collectively, these data suggest an effect of the series on proper
assembly of fully processed CA protein in nascent viral particles.
Disruption of the Formation of Native-Like Particles
To observe the effects of this class of compound on the
morphology of nascent viral particles, PBMCs were infected with
HIV NL4-3 either in the absence or presence of PF-3450074 at
7 mM( ,106 EC50). The cells and resulting viral products were
fixed and treated for transmission electron microscopy (TEM).
In untreated infections, approximately 66% of particles (78/118
observed) were native-like, as defined by being ,100nm in
diameter and having a distinct central density representative of a
mature capsid core). A close in view of a native-like particle from
an untreated culture (Fig. 4a) clearly illustrates the conical capsid
core in the center of the virion. A wider view shows the high level
of uniformity among the particles produced in the untreated
infections (Fig. 4b). Both native-like and apparent immature
particles are present at consistent shape and size. In contrast,
native-like particles were not observed in PF-3450074-treated
infections. The particles produced in PF-3450074-treated infec-
tions lack a clear central density representative of a mature capsid
(Fig. 4c). Consistent with the observation that these compounds do
not affect p24 levels, the number of particles in PF-3450074-
treated infections appears similar to untreated, however the
morphology and size of particles is highly variable (Fig. 4d).
Compound Effects on CA Multimerization
The simplest explanation to reconcile the data above involves a
model where thisnew class of inhibitorstargets both early (viral core
uncoating) and late (viral core assembly) events in the replication
cycle by affecting CA – CA interactions and thus core stability. To
studytheeffectsoncapsidassembly,weevaluatedtheinhibitorsinin
vitro CA multimerization assays [10]. Such assays can be used to
measure the effect of compounds on the rate of formation of higher
order CA multimers or tubes that are widely thought to represent
many aspects of native core structure. Addition of PF-3450074
results in a significant increase in the rate of CA multimerization
(Fig. 3d). In contrast, a structural analogue withno antiviral activity,
PF-4159193 (Fig. S2), did not affect the kinetics of CA multi-
merization, indicating that this profound effect is correlated with
antiviralactivityandnotageneralphysicaleffect ofthisseries.Aswe
have reproduced with the CAIpeptide (Fig. 3d), all of the previously
reported HIV CA assembly inhibitors decreased the rate of
multimerization in this assay [10,11,12]. These data demonstrate
indirectly that PF-3450074 interacts with HIV-1 CA and further
suggest a mechanism that is fundamentally distinct from previously
reported HIV CA inhibitors.
High Resolution Co-Crystal Structure Reveals a Novel
Binding Pocket
To further understand the mode of action of this novel class of
compounds, wedeterminedthe crystalstructureofHIV-1CANTD
protein in complex with PF-3450074 using a CA protein construct
that contained a single glycine residue in place of the cyclophilin
binding loop (residues 87–99). Although the cyclophilin binding
loop is important for viral infection, it is not required for proper
HIV CA protein folding and in vitro multimerization function [8].
Binding affinity of PF-3450074 to the crystallographic construct
(Kd=3.42 mM) is similar to that observed for both full length
wild type CA (Kd=2.79 mM) and isolated wild type NTD
(Kd=2.24 mM), as measured by isothermal titration calorimetry.
Using this construct, the co-crystal structure of PF-3450074 was
solved with the NTD of HIV-1 CA to 1.8 A ˚ resolution. The
structure of the complex showed that the overall fold of the CA
protein is the same as previously described CA structures [19,20,21]
andillustratesthatneitherthecompound,PF-3450074,northe loop
deletioncausedanysignificantshiftsintheproteinstructure(Fig.5a).
PF-3450074 occupies a preformed pocket in the HIV-1 CA
NTD bounded by helices 3, 4, 5 and 7 (Fig. 5a). The R1 and R2
aromatic moieties of the compound occupy two hydrophobic sub-
pockets and provide most of the key interactions which anchor the
compound to the NTD (Fig. 5b). The indole substituent protrudes
from the NTD R3 sub-pocket close to Lys70. The binding site for
PF-3450074 is distinct from the sites targeted by CAP-1 and CAI/
NYAD-1 [10,11,22,23,24]. These results confirm that PF-3450074
directly binds HIV CA and are consistent with this class of
inhibitors acting via a unique mechanism. Coordinates are stored
in the Protein Data Bank (PDB ID code 2XDE).
Discussion
We describe a novel class of inhibitors that target HIV CA by a
unique mechanism that interferes with both early and late events
in the viral replication cycle. HIV CA plays an essential role in
several stages of viral replication and is viewed as an important, yet
Novel Mechanism and Binding Site for HIV Capsid
PLoS Pathogens | www.plospathogens.org 5 December 2010 | Volume 6 | Issue 12 | e1001220Figure 5. Structure of the novel inhibitor binding site and context in the NTD. a) Overlays of capsid structures with PF-3450074 in blue and
CAP-1 in pink bound to capsid N-terminal domain; b) Close up view of PF-3450074 site (binding site residues labelled in black, R1-3 sub-pockets
labelled in purple). In the R1 sub-pocket PF-3450074 makes hydrophobic interactions with Ile-73, Ala-105, Thr-107, Tyr-130 and a stacking interaction
with the side chain of Asn-53. The benzyl group R2 makes a number of hydrophobic interactions in a sub-pocket formed by the side chains of Met66,
Leu69, Val59, Ile-73 and Leu-56. The R3 sub-pocket is only partially occupied by the indole group, forming interactions with the side chains of Met-66,
Gln-67, Lys-70 and Gln-63 amide. The indole NH forms a hydrogen bond interaction with the side chain amide of Gln-67 via a water molecule, while
an Asn-57 forms a key hydrogen bond with the cis amide bond of PF-3450074. c) Location of resistant mutations (purple) in relation to PF-3450074
capsid binding site. (PDB ID code 2XDE).
doi:10.1371/journal.ppat.1001220.g005
Figure 4. EM analysis of the effects of PF-3450074 on nascent viral particles. PBMCs were infected with HIV NL4-3 in medium containing
either no compound or 7mM PF-3450074. The cells and resulting viral products were processed and observed by transition electron microscopy. Close
in view of an untreated native-like particle (a) reveals the central conical capsid structure, while a wider view (b) shows the high level of uniformityi n
morphology and size among untreated particles. Close in view of PF-3450074-treated particles (c) shows consistent loss of the central capsid density,
and a wider view (d) illustrates a much wider range in particle morphology and size.
doi:10.1371/journal.ppat.1001220.g004
Novel Mechanism and Binding Site for HIV Capsid
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series demonstrates that small molecules targeting HIV CA can
have potent broad-spectrum antiviral activity. We demonstrate
directly that HIV CA is the antiviral target of these inhibitors in
infected cells by showing that mutations in HIV CA confer
resistance to several members of the series. EM analysis shows that
the series profoundly affects the morphology of nascent HIV
particles. We demonstrate that the compounds affect CA protein
multimerization in vitro and we have elucidated details of the novel
compound binding site on HIV CA by solving a co-crystal
structure of a compound from the series bound to the NTD of the
protein. Our data strongly suggest that this new series of inhibitors
targets HIV CA function during both the virion uncoating and
viral core assembly processes.
Previous studies have described two molecules that target HIV-1
CA assembly in vitro, CAP-1 (a small molecule) and CAI (a
dodecapeptide) [10,11,12]. CAP-1 acts in the late stage of viral
replication and does not inhibit HIV-1 infection when added to pre-
formed HIV-1 particles. A cell-permeable derivative of CAI,
NYAD-1, inhibits formation of both immature and mature HIV-1
virus particles as well as early events in the replication cycle at low
micromolar concentrations. The properties of the new class of CA
inhibitorsdescribed inthisstudyareclearlydistinguishedfrom those
of other HIV-1 inhibitors, including previously described CA
inhibitors. Unlike CAP-1,the small molecules described hereinhibit
both early and late events in the HIV replication cycle. In addition,
PF-3450074 did not inhibit Gag particle production from HIV-1
transfected cells, suggesting that the compound series does not affect
immature particle assembly. This is in contrast to the effects on
immature particle assembly reported for NYAD-1. A co-crystal
structure of a representative compound (PF-3450074) demonstrated
a new binding site on HIV-1 CA distinct from those described for
CAP-1 or CAI. Furthermore, PF-3450074 increased the rate of
HIV-1CA multimerization in vitro, whileCAIand CAP-1decreased
the rate of CA multimerization in the same assay. While this does
not necessarily define the action of these compounds on replicating
virus, it does suggest a fundamentally different mechanism of
inhibition from that of previously described CA inhibitors.
The proposed mechanism of action for both the early and late
stage activities of this new class of inhibitors involves a direct effect
on higher-order structures of HIV CA, in assembly and uncoating.
Although the present data do not indicate whether the compounds
enhance or inhibit the uncoating process, either effect is likely to
interfere with proper reverse transcription [25]. HIV-1 capsid
mutations proximal to the PF-3450074 binding pocket have been
described that either destabilize or enhance the stability of viral
cores and result in specific postentry defects in virus replication
[24]. It is possible that such mutations and the compounds
described in this study have analogous effects on inter-subunit
capsid interactions. To gain further insights into the mode of
action of PF-3450074, we generated a model of an assembled
capsid hexamer in complex with PF-3450074 (Fig. 6a) based on
superpositioning of published assembled capsid structures [13,14]
with the structure of the PF-3450074/CA complex. In the model,
the R3 indole group which protrudes from the NTD in our
structure localizes to the interface between capsid monomers in an
assembled capsid and sits directly between the NTD of one capsid
monomer and the C-terminal domain of another, making contacts
to Tyr-169, Leu-172, Arg-173, Gln-179, and Lys-182 (Fig. 6b).
This suggests the R3 indole group of PF-3450074 could play a
critical role in modulating inter-subunit interactions. Both the CA
NTD contact residues described by the co-crystal structure and
these putative C-terminal contacts are well conserved across viral
strains (Tables S5 and S6). This is consistent with the broad-
spectrum antiviral activity observed for this series.
Although the sum of our results suggests a mechanism that
affects interactions between capsid monomers, the early stage
activity is consistent with other models. Cyclophilin A plays a
critical role in the early stages of HIV-1 replication through
interactions with the viral capsid [26]. Also, capsid-binding
restriction factors such as the tripartite motif containing (TRIM)
proteins prevent the infection of many primate cells with HIV or
SIVs from other species [5,9]. Thus, based on our data, we cannot
dismiss the possibility that, during early infection, this new series
might affect specific capsid-host protein interactions that mediate
the viral uncoating process. A detailed study of the early stage
Figure 6. Model of inhibitor effects at the NTD-CTD interface. a) Model of HIV-1 capsid in hexameric complex with PF-3450074 bound in each
of the binding pockets (each of the six full-length CA monomers are coloured differently); b) Close up view of model of interface between adjacent N-
terminal subunits (green and blue) and the C-terminal domain of an adjacent monomer (pink) in assembled capsid. PF-3450074 highlighted in purple.
Residues highlighted Pro38 (adjacent N-terminal domain green), Thr-107, Thr-58, Asn-57, Asn-53, Lys-70 (N-terminal domain blue), Tyr-169, Leu-172,
Arg-173, Gln-179, Lys-182 (C-terminal domain pink).
doi:10.1371/journal.ppat.1001220.g006
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the HIV-1 capsid and a dependence on cyclophilin A, indicating
that the compound induces premature uncoating of the virus,
potentially through a mechanism similar to that of TRIM
restriction [27].
In this study, we identify a new binding site on HIV-1 CA that
can be targeted by small molecule inhibitors resulting in broad-
spectrum antiviral activity. In addition, we describe the discovery
and characterization of a novel series of compounds that act at this
site and inhibit the virus at two points in the replication cycle. This
series should serve as a good starting point for the development of
a new class of HIV therapeutics through structure-based drug
design or other approaches. The broad spectrum activity of this
series is particularly exciting and highlights this novel mechanism
as a significant therapeutic opportunity.
Material and Methods
Cells, Virus, and Compounds
HeLa CD4 LTR/beta-Gal, MT-2, PM1, CEM-SS and HEK
293 cells as well as pNL4-3 HIV-1 infectious clone, HIV-1 IIIB,
HIV-1 RF, HIV-1 BaL, and all primary isolates were obtained
throughtheNationalInstitutesofHealth(NIH)AIDSResearchand
Reference Reagent Program, Bethesda, MD. JC53BL cells were
sourced from Tranzyme. Efavirenz (EFV) was kindly provided by
DuPont Merck (Wilmington, DE). Nelfinavir (NFV), 135137, PF-
3450074, and PF-3759857 were synthesized by Pfizer Inc.
Cytopathic Effect Assays (CPE)
As described [18], host cells were infected with HIV-1 NL4-3,
HIV-1 IIIB, HIV-1 RF. The cytopathic effect was measured using
XTT reagent and the therapeutic index (TI) calculated by dividing
the CC50 (mock infected cells) value by the EC50.
Clinical Isolate Antiviral Assays
PHA-stimulated PBMC’s were incubated for 1 hour with virus at
an moi of 0.001–0.01. They were plated in 96-well plates at 5610
5
cells/ml and incubated for 5 days at 37uC.10 mL of the supernatant
was then transferred to a plate containing 40 mL of JC53BL cells at
0.5610
5 cells/ml. After 2 days, the cells were processed for b-
galactosidase activity using the FluorAce kit (Bio-Rad). PF-3794231
wastestedagainst clinical isolates at the Southern Research Institute
(Frederick, MD) as previously described [18].
Single-Cycle Infection Assays
The single-cycle infectious HIV-1 reporter viruses were
generated as previously described [28] by co-transfecting
HEK293 cells with an HIV-1 NL4-3 single-cycle infectious cDNA
(pNL4-3deltaEnv) and an NL4-3 or VSV-G envelope expression
vector. Half-log dilutions of test compounds were added to HeLa
CD4 LTR/beta-Gal target cells, seeded in 96-well plates at a cell
density of 1610
4 cells per well in DMEM containing 10% FBS.
Compound-treated or compound-free target cells were then
infected with the HIV-1 single-cycle infectious virus and after
72 hours measured for the induction of beta-galactosidase Data
were expressed as the percent of reporter gene activity in infected
compound-treated cells relative to that of infected, compound-free
cells.
Virus Production-Infectivity Assays
Envelope-deleted NL4-3 cDNA (pNL4-3deltaEnv) was co-
transfected into HEK 293 cells with an HIV envelope expression
vector as previously described [29]. Half-log dilutions of test
compounds were then added to transfected cell cultures 3 hrs after
transfection. The supernatants were harvested 72 hrs after
transfection and infectious virus production was subsequently
quantified by measuring the induction of the beta-galactosidase
reporter gene after 100-fold dilution into fresh medium and
incubation in the presence of HeLa CD4 LTR/beta-Gal target
cells for 72 hours.
Selection and Characterization of Resistant Virus
Viral variants resistant to PF-1385801 or PF-3759857 were
selected as described previously [18]. To construct NL4-3
recombinant virus containing the Q67H, K70R, Q87P, T107N
and L111I amino acid substitutions identified in the serial passage
studies, viral cDNAs that had been TOPO cloned for sequence
analysis were digested with BssHII and ApaI and ligated back into
a wild type pNL4-3 background. The effect of amino acid
substitutions in HIV-1 Gag sequences on PF-3759857 susceptibil-
ity was measured in HIV Replication assays as described
previously [15].
Protein Expression and Purification
Proteins were expressed in E. Coli BL21(DE3) in 2YT
containing kanamycin. Cells were harvested following induction
with IPTG and growth overnight at 20uC. CA1-231 was purified as
described [30]. For CA1-146/D87-99G, cells were resuspended and
lysed in buffer A (50 mM TrisHCl pH 7.4, 150 mM NaCl,
10 mM imidazole, and 2 mM b-mercaptoethanol). The lysate was
clarified by centrifugation, filtered then applied to a His trap nickel
affinity column (Sigma), eluting with buffer A supplemented with
300 mM imidazole. The eluted material was further purified on a
Sephacryl 100HR column in 50 mM TrisHCl pH 7.4, 150 mM
NaCl and 2 mM b-mercaptoethanol.
HIV Capsid Multimerisation Assay
Multimerisation assays were performed as previously described
[10]. Compound was added to 30 mg of full-length CA protein in
50 mM sodium phosphate buffer, pH 8.0 in a volume of 30 ml.
Capsid assembly was initiated by addition of a concentrated NaCl
solution (50 ml 5 M NaCl in 50 mM sodium phosphate, pH 8.0).
Optical density was monitored on a Molecular Devices Spec-
traMax spectrophotometer at 350 nm every 20 s for 1 h.
Transmission Electron Microscopy (TEM)
PBMCs were incubated with 7 mM PF-3450074 (approx. 106
IC50), for 30 minutes before being infected with mock virus
(medium alone), or with NL4-3 at an MOI of 1. At 72 hours post-
infection the supernatants were removed and the cells were fixed
for 60 min in MacDowell’s fixative (4% (v/v) paraformaldehyde,
1% glutaraldehyde in 0.1M phosphate Milliong buffer, pH 7.3) at
4 C. The cells were rinsed in 0.15M Phosphate So ¨rensen buffer
with 0.2% (v/v) NaCl (pH 7.3) and suspended in warm 3.5% agar
in water. The agar blocks were cooled to 4uC and washed three
times for 10 minutes in 0.15M Phosphate So ¨rensen buffer with
0.2% (v/v) NaCl (pH 7.3). The agar blocks with the cells were
stained using 2% Osmium tetroxide in 0.3M phosphate So ¨rensen
buffer (pH 7.4) for 1 h at 4uC. The blocks were washed 4 times for
10 minutes in sterilized water at room temperature before they
were dehydrated in graded ethanol (50%, 70%, 90%, 100%,
100%) for 15 minutes at each concentration at room temperature.
The blocks were treated with propylene oxide three times for
15 minutes in room temperature before the resin was infiltrated
for 1 hour at room temperature with a 1:1 propylene oxide:Epon
mix (Epon contains epoxy embedding medium 20 mL (Epon 812
resin)) and 12 ml MNA (methyl nadic anhydride) and 9 ml DDSA
Novel Mechanism and Binding Site for HIV Capsid
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epon overnight at room temperature. The resin was then
embedded with Epon and BDMA 3% for 1 hour at room
temperature. The resin was polymerised for 48h at 58–60uC.
Approximately 1 micron thick semi-thin sections were cut and
stained in toluidine blue and observed in light microscopy.
Subsequently, ultra-thin sections of 70–90 nm were cut on an
Ultracut E Reichert microtone, and stained with uranyl acetate
and lead citrate. Observations were made using a Jeol 1200 EX II
electron microscope.
Isothermal Calorimetry
Isothermal titration calorimetry (ITC) was performed using the
VP-ITC calorimetric system (GE Healthcare). Protein solutions for
ITC were dialyzed against buffer A (50 mM TrisHCl pH 7.5/
150 mM NaCl/2 mM b-mercaptoethanol). The dialyzed protein
solution (15 mM) in the calorimetric cell (1.4274 ml) was titrated at
25uC with ligand (200 mM) in the buffer A using 162 mL, followed
by 25610 mL injections. Heat evolved was obtained from the
integral of the calorimetric signal and heat of dilution was
negligible in titrations of the ligand into buffer only. Analysis was
carried out with Origin 5.0 software (GE Healthcare). Binding
parameters such as the number of binding sites (n), the binding
constant (Ka,M
21), and the binding enthalpy (DHa, kcal/mol of
bound ligand) were determined by fitting the experimental binding
isotherms.
Protein Crystallization, Data Collection, and Structure
Refinement
Protein was concentrated to 30 mg/ml and inhibitor added to
5 mM from a 100 mM DMSO stock solution. After standing for
2 hours, hanging drop crystallizations were set up consisting of
2 ml of protein and 1 ml of well solution (20% PEG 8000, 100 mM
phosphate-citrate pH 4.2 and 200 mM sodium chloride). Crystals
grew overnight at room temperature and were frozen for X-ray
data collection following addition of 60% NDSB containing 40%
ethylene glycol (4 ml). Data was collected at the ESRF (ID14-4) on
an ADSC Q315 detector, integrated with mosflm [31] and scaled
with CCP4 package SCALA [32]. The structure was solved by
molecular replacement using MOLREP [32] with a truncated
model of the N-terminal CA. The structure was refitted using
QUANTA version 2000.1 (Accelrys Inc., San Diego, CA) and
refinement was carried out using REFMAC [33]. Data collection
and refinement statistics are shown in Table S7. Coordinates are
stored in the Protein Data Bank (PDB ID code 2XDE).
Supporting Information
Table S1 In Vitro Antiviral Activity of PF-3450074 Against
Different HIV-1 Clinical Isolates or Laboratory Strains in PBMCs
Found at: doi:10.1371/journal.ppat.1001220.s001 (0.08 MB PDF)
Table S2 In Vitro Antiviral Activity of PF-3759857 Against
Different HIV-1 Clinical Isolates or Laboratory Strains in PBMCs
Found at: doi:10.1371/journal.ppat.1001220.s002 (0.09 MB PDF)
Table S3 In Vitro Antiviral Activity of Efavirenz Against
Different HIV-1 Clinical Isolates or Laboratory Strains in PBMCs
Found at: doi:10.1371/journal.ppat.1001220.s003 (0.08 MB PDF)
Table S4 In Vitro Antiviral Activity of AZT Against Different
HIV-1 Clinical Isolates or Laboratory Strains in PBMCs
Found at: doi:10.1371/journal.ppat.1001220.s004 (0.09 MB PDF)
Table S5 Conservation of capsid binding site residues across
HIV-1 strains
Found at: doi:10.1371/journal.ppat.1001220.s005 (0.08 MB PDF)
Table S6 Conservation of capsid binding site residues across
HIV-2 strains
Found at: doi:10.1371/journal.ppat.1001220.s006 (0.08 MB PDF)
Table S7 Crystallographic Data Collection and Refinement
Statistics
Found at: doi:10.1371/journal.ppat.1001220.s007 (0.06 MB PDF)
Figure S1 Effect of PF-3450071 on proteolytic process-
ing of HIV-1 Gag. For the Western blot analyses, HEK 293 cells
were transfected with pNL4-3 in the presence or absence of
compound, and supernatants were harvested 72h later. Infectious
virus production was measured using a portion of the supernatants
of transfected cells in virus production/infection assays as
described in materials and methods. Western blot of the
supernatants was generated as previously described in reference
17. Virus expression in the presence of the protease inhibitor NFV
displays an array of unprocessed forms of the Gag polyprotein,
however PF-3450071, has no effect on proteolytic processing of
Gag, even at highly inhibitory concentrations.
Found at: doi:10.1371/journal.ppat.1001220.s008 (0.05 MB PDF)
Figure S2 Structure of PF-4159193
Found at: doi:10.1371/journal.ppat.1001220.s009 (0.00 MB PDF)
Acknowledgments
We thank the NIH AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH for providing the reagents listed in the
Materials and Methods section.
Author Contributions
Conceived and designed the experiments: WSB CP SLB. Performed the
experiments: SLI MA RB JC JI LJ RH AK JAN ADS KW HW. Analyzed
the data: WSB CP DGB GC AKP MP KW SLB. Wrote the paper: WSB
CP SLI SLB.
References
1. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, et al. (2008)
Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the
International AIDS Society-USA Panel. JAMA 300: 555–570.
2. Taiwo B (2009) Understanding transmitted HIV resistance through the
experience in the USA. International Journal of Infectious Diseases 13: 552–559.
3. Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S (2010) Evolutionary
dynamics of complex networks of HIV drug-resistant strains: the case of San
Francisco. Science 327: 697–701.
4. Adamson CS, Freed EO (2010) Novel approaches to inhibiting HIV-1
replication. Antiviral Research 85: 119–141.
5. Mascarenhas AP, Musier-Forsyth K (2009) The capsid protein of human
immunodeficiency virus: interactions of HIV-1 capsid with host protein factors.
FEBS Journal 276: 6118–6127.
6. Neira J (2009) The capsid protein of human immunodeficiency virus: designing
inhibitors of capsid assembly. FEBS Journal 276: 6110–6117.
7. Ako-Adjei D, Johnson MC, Vogt VM (2005) The Retroviral Capsid Domain
Dictates Virion Size, Morphology, and Coassembly of Gag into Virus-Like
Particles. J Virol 79: 13463–13472.
8. Ganser-Pornillos BK, von Schwedler UK, Stray KM, Aiken C, Sundquist WI
(2004) Assembly properties of the human immunodeficiency virus type 1 CA
protein. J Virol 78: 2545–2552.
9. Aiken C (2006) Viral and cellular factors that regulate HIV-1 uncoating. Curr
Opin HIV AIDS 1: 194–199.
10. Tang C, Loeliger E, Kinde I, Kyere S, Mayo K, et al. (2003) Antiviral inhibition
of the HIV-1 capsid protein. J Mol Biol 327: 1013–1020.
11. Sticht J, Humbert M, Findlow S, Bodem J, Muller B, et al. (2005) A peptide
inhibitor of HIV-1 assembly in vitro. Nat Struct Mol Biol 12: 671–677.
12. Zhang H, Zhao Q, Bhattacharya S, Waheed AA, Tong X, et al. (2008) A Cell-
penetrating Helical Peptide as a Potential HIV-1 Inhibitor. Journal of Molecular
Biology 378: 565–580.
Novel Mechanism and Binding Site for HIV Capsid
PLoS Pathogens | www.plospathogens.org 9 December 2010 | Volume 6 | Issue 12 | e100122013. Ganser-Pornillos BK, Cheng A, Yeager M (2007) Structure of Full-Length HIV-
1 CA: A Model for the Mature Capsid Lattice. Cell 131: 70–79.
14. Pornillos O, Ganser-Pornillos BK, Kelly BN, Hua Y, Whitby FG, et al. (2009)
X-ray structures of the hexameric building block of the HIV capsid. Cell 137:
1282–1292.
15. Cao J, Isaacson J, Patick AK, Blair WS (2005) High-throughput human
immunodeficiency virus type 1 (HIV-1) full replication assay that includes HIV-1
Vif as an antiviral target. Antimicrob Agents Chemother 49: 3833–3841.
16. Butler SL, Hansen MS, Bushman FD (2001) A quantitative assay for HIV DNA
integration in vivo. Nat Med 7: 631–634.
17. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, et al. (2003) PA-457:
A potent HIV inhibitor that disrupts core condensation by targeting a late step in
Gag processing. Proceedings of the National Academy of Sciences of the United
States of America 100: 13555–13560.
18. Blair WS, Cao J, Fok-Seang J, Griffin P, Isaacson J, et al. (2009) New Small-
Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1
Virion Maturation. Antimicrob Agents Chemother 53: 5080–5087.
19. Kelly BN, Howard BR, Wang H, Robinson H, Sundquist WI, et al. (2006)
Implications for Viral Capsid Assembly from Crystal Structures of HIV-1
Gag(1–278) and CA(N)(133–278). Biochemistry 45: 11257–11266.
20. Gamble TR, Vajdos FF, Yoo S, Worthylake DK, Houseweart M, et al. (1996)
Crystal structure of human cyclophilin A bound to the amino-terminal domain
of HIV-1 capsid. Cell 87: 1285–1294.
21. Monaco-Malbet S, Berthet-Colominas C, Novelli A, Battai N, Piga N, et al.
(2000) Mutual conformational adaptations in antigen and antibody upon
complex formation between an Fab and HIV-1 capsid protein p24. Structure 8:
1069–1077.
22. Kelly BN, Kyere S, Kinde I, Tang C, Howard BR, et al. (2007) Structure of the
Antiviral Assembly Inhibitor CAP-1 Complex with the HIV-1 CA Protein.
Journal of Molecular Biology 373: 355–366.
23. Ternois F, Sticht J, Duquerroy S, Krausslich HG, Rey FA (2005) The HIV-1
capsid protein C-terminal domain in complex with a virus assembly inhibitor.
Nat Struct Mol Biol 12: 678–682.
24. Bhattacharya S, Zhang H, Debnath AK, Cowburn D (2008) Solution structure
of a hydrocarbon stapled peptide inhibitor in complex with monomeric C-
terminal domain of HIV-1 capsid. J Biol Chem 283: 16274–16278.
25. Forshey BM, von Schwedler U, Sundquist WI, Aiken C (2002) Formation of a
Human Immunodeficiency Virus Type 1 Core of Optimal Stability Is Crucial
for Viral Replication. J Virol 76: 5667–5677.
26. Luban J (2007) Cyclophilin A, TRIM5, and Resistance to Human Immuno-
deficiency Virus Type 1 Infection. J Virol 81: 1054–1061.
27. Shi J, Zhou J, Shah VB, Aiken C, Whitby K (2010) Small Molecule Inhibition of
Human Immunodeficiency Virus Type 1 Infection by Virus Capsid Destabi-
lization. J Virol;epub ahead of print.
28. Blair WS, Isaacson J, Li X, Cao J, Peng Q, et al. (2005) A novel HIV-1 antiviral
high throughput screening approach for the discovery of HIV-1 inhibitors.
Antiviral Research 65: 107–116.
29. Blair WS, Cao J, Jackson L, Jimenez J, Peng Q, et al. (2007) Identification and
Characterization of UK-201844, a Novel Inhibitor That Interferes with Human
Immunodeficiency Virus Type 1 gp160 Processing. Antimicrob Agents
Chemother 51: 3554–3561.
30. Lanman J, Sexton J, Sakalian M, Prevelige PE Jr (2002) Kinetic analysis of the
role of intersubunit interactions in human immunodeficiency virus type 1 capsid
protein assembly in vitro. J Virol 76: 6900–6908.
31. Leslie AGW (1992) mosflm. Joint CCP4+ESF-EAMCB Newsletter on Protein
Crystallography, No 26.
32. Collaborative Computational Project N (1994) The CCP4 Suite: Programs for
protein crystallography. Acta Crystallographica Section D Biological Crystal-
lography 50: 760–763.
33. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular
structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystal-
logr 53: 240–255.
Novel Mechanism and Binding Site for HIV Capsid
PLoS Pathogens | www.plospathogens.org 10 December 2010 | Volume 6 | Issue 12 | e1001220